Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Zymeworks Inc. Common Stock
ZYMECurrent price
15.39 USD
-0.84 USD (-5.15%)
Last closed
16.26 USD
Company
www.zymeworks.com
ISIN
CA98985W1023
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 145 432 832 USD
Yield for 12 month
+97.81 %
1Y
3Y
5Y
10Y
15Y
ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. Address: 108 Patriot Drive, Middletown, DE, United States, 19709
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
17.44 USDP/E ratio
–Dividend Yield
–Current Year
+76 012 000 USD
Last Year
+412 482 000 USD
Current Quarter
+16 000 000 USD
Last Quarter
+19 243 000 USD
Current Year
-66 977 000 USD
Last Year
+412 482 000 USD
Current Quarter
+13 337 000 USD
Last Quarter
+16 714 000 USD
Key Figures ZYME
1 year
3 years
5 years
10 years
EBITDA
-114 707 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-14.69 %
PEG Ratio
–
Return On Equity TTM
-28.73 %
Wall Street Target Price
17.44 USD
Revenue TTM
62 199 000 USD
Book Value
5.27 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-3.1 %
Dividend Yield
–
Gross Profit TTM
203 779 000 USD
Earnings per share
-1.49 USD
Diluted Eps TTM
-1.49 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-182.75 %
Dividend Analytics ZYME
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ZYME
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ZYME
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
13.963
Price Sales TTM
18.4156
Enterprise Value EBITDA
0.3383
Price Book MRQ
3.1213
Financials ZYME
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ZYME
For 52 weeks
7.42 USD
17.36 USD
50 Day MA
13 USD
Shares Short Prior Month
4 049 768
200 Day MA
10.74 USD
Short Ratio
6.9
Shares Short
4 163 667
Short Percent
7.42 %
BeatStart